MedCity News March 23, 2025
Creating adequate capacity for any therapeutic can be challenging, and the specialized technologies for manufacturing complex biologics require flexibility and agility in production processes. Here’s how contract development and manufacturing organizations (CDMOs) ensure that biopharmaceutical companies have a partner with the speed, flexibility, and expertise necessary for successful drug development and manufacturing.
The use of biologics is rapidly increasing as new drugs are approved for label expansions. Monoclonal antibodies, multispecific antibodies, and antibody-drug conjugates (ADCs) are being implemented in an array of fields, including oncology, immunology, and neurology. As clinical demand for biologics increases, biopharmaceutical companies must ensure that they have the manufacturing capacity available to produce enough biologics. Creating adequate capacity for any therapeutic can be challenging, and the...
Today's Sponsors
Today's Sponsor
